Pozen initiates a new business model as a specialty pharma. The debate is focusing on whether it works.

Limit by time, I won't go to the details. A simple answer is "so far so good." However, we need to wait for 2011 Vimovo numbers to have an ironical answer.

Dr. Plachetka's outlook for PA marketability is very reasonable. I like Dr. Plachetka's word "never say never." I hope Pozen will be flexible enough to face the chellanges and do whatever the best for shareholders. Good Luck to all.